Morgan Stanley Verastem, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.39 - $0.71 $5,714 - $10,403	-14,653 Reduced 9.16%	145,241 $61,000
Q4 2022 Feb 14, 2023	SELL	$0.33 - $10.44 $11,931 - $377,479	-36,157 Reduced 18.44%	159,894 $63,000
Q3 2022 Nov 14, 2022	SELL	$0.92 - $11.16 $92,076 - $1.12 Million	-100,083 Reduced 33.8%	196,051 $167,000
Q2 2022 Oct 27, 2022	BUY	$1.02 - $1.83 $1,604 - $2,878	1,573 Added 0.53%	296,134 $344,000
Q2 2022 Aug 15, 2022	BUY	$1.02 - $1.83 $1,604 - $2,878	1,573 Added 0.53%	296,134 $344,000
Q1 2022 Oct 27, 2022	SELL	$1.06 - $2.1 $1,667 - $3,303	-1,573 Reduced 0.53%	294,561 $415,000
Q1 2022 May 13, 2022	BUY	$1.06 - $2.1 $51,143 - $101,322	48,249 Added 19.59%	294,561 $415,000
Q4 2021 Feb 14, 2022	BUY	$2.05 - $3.2 $112,530 - $175,657	54,893 Added 28.68%	246,312 $506,000
Q3 2021 Nov 15, 2021	BUY	$2.54 - $4.07 $486,204 - $779,075	191,419 New	191,419 $589,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.17B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.